Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AVXL | Stock Option (Right to Buy) | Award | $0 | +125K | $0.00 | 125K | Dec 19, 2024 | Common Stock | 125K | $5.36 | Direct | F1 |
Id | Content |
---|---|
F1 | On February 20, 2024, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was regulatory submission of AD-004 for Alzheimer's disease (US or EU). The performance criteria for this milestone was met with the acceptance of the MAA filing by the EMA, resulting in vesting of the option as to 125,000 shares. |